JCR Pharmaceuticals Co Ltd 2020 Integrated Report
The report presents FY2019 consolidated net sales of 24,781 million yen, the eighth consecutive year of growth, while R&D expenditures reached 5,997 million yen. It highlights JCR's rare-disease pipeline, including JR-141 in Phase III in Japan and Phase II in Brazil, as well as the acquisition of ArmaGen in 2020. Sustainability coverage spans rare diseases, environment, society, and corporate governance, with FY2019 energy use of 3,784 kl and CO2 emissions of 426 tons.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2020
Type: Integrated Report
Pages: 68
Back to company
JCR Pharmaceuticals Co Ltd
Jcr Report
The report presents FY2019 consolidated net sales of 24,781 million yen, the eighth consecutive year of growth, while R&D expenditures reached 5,997 million yen. It highlights JCR's rare-disease pipeline, including JR-141 in Phase III in Japan and Phase II in Brazil, as well as the acquisition of ArmaGen in 2020. Sustainability coverage spans rare diseases, environment, society, and corporate governance, with FY2019 energy use of 3,784 kl and CO2 emissions of 426 tons.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees